NCT06741722招募中2 期
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for Relapsed/refractory Acute Myeloid Leukemia
Beijing 302 Hospital1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年10月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Complete remission rate
研究概览
简要总结
The DCMG regimen includes decitabine or azacitidine (hypomethylating agents), mitoxantrone liposome, cytarabine, and granulocyte colony-stimulating factor (G-CSF), comprising four medications. This project initiates a prospective and exploratory clinical study on the DCMG chemotherapy regimen for the treatment of relapsed/refractory AML (Acute Myeloid Leukemia). The study aims to evaluate the efficacy and safety of the DCMG combination chemotherapy regimen in treating relapsed/refractory AML.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient has fully understood the study, voluntarily agrees to participate, and has signed the Informed Consent Form (ICF);
- •Age between 18 and 75 years, with no gender restrictions;
- •Confirmed diagnosis of relapsed/refractory AML (Acute Myeloid Leukemia) by pathology (meeting any one of the following criteria):
- •Patients who meet the diagnostic criteria for acute myeloid leukemia (AML) with minimal residual disease (MRD) positivity;
- •Or patients who meet the diagnostic criteria for recurrent AML, or refractory AML;
- •Serum total bilirubin ≤ 1.5 times the upper limit of normal, serum ALT and AST both ≤ 2.5 times the upper limit of the normal range, serum creatinine ≤ 1.5 times the upper limit of normal;
- •Echocardiogram showing left ventricular ejection fraction (LVEF) ≥ 50%;
- •Estimated survival time ≥ 3 months;
- •ECOG performance status score of 0-2.
排除标准
- •The subject's prior anti-tumor treatment history meets one of the following conditions:
- •Previously received mitoxantrone or mitoxantrone hydrochloride liposome injection;
- •Previously received doxorubicin or other anthracyclines, with a total cumulative dose of doxorubicin > 360 mg/m² (other anthracycline drugs are converted at a ratio of 1 mg doxorubicin equivalent to 2 mg daunorubicin or 0.5 mg idarubicin);
- •Cardiac function and disease meet any of the following conditions:
- •Long QTc syndrome or QTc interval > 480 ms;
- •Complete left bundle branch block, second-degree or third-degree atrioventricular block;
- •Severe, uncontrolled arrhythmia requiring medication;
- •New York Heart Association (NYHA) classification ≥ Class II;
- •Ejection fraction (EF) < 50% or below the lower limit of normal for the study center's laboratory;
- •History of myocardial infarction, unstable angina, severe unstable ventricular arrhythmias, or any other arrhythmia requiring treatment, clinically significant pericardial disease, or evidence on electrocardiogram of acute ischemia or active conduction system abnormalities within 6 months prior to enrollment.
- •Underwent any major surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, or experimental treatment within 2 weeks before the first administration of the study drug;
- •Uncontrolled systemic diseases (such as progressive infections, uncontrolled hypertension, diabetes, etc.);
- •Previous or current diagnosis of other malignancies (excluding adequately controlled basal cell carcinoma of the skin that is non-melanoma, breast/cervical carcinoma in situ, or other malignancies that have been adequately controlled without treatment in the past five years);
- •Active hepatitis B or C infection during the viremic phase (Hepatitis B testing: if either HBsAg or core antibody is positive, add HBV-DNA testing; viral DNA levels exceeding 1x10^3 copies/mL; Hepatitis C testing: if HCV antibody is positive, add HCV-RNA testing; viral RNA levels exceeding 1x10^3 copies/mL);
- •Human Immunodeficiency Virus (HIV) infection (HIV antibody positive);
- •Pregnant women, breastfeeding women, patients who refuse to use effective contraception during the study period;
- •Significant neurological or psychiatric history;
- •Patients deemed unsuitable for participation in this study by the investigator.
研究组 & 干预措施
DCMG
Experimental
Patients are treated with DCMG chemotherapy regimen.
干预措施: Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF (Drug)
结局指标
主要结局
Complete remission rate
时间窗: At the end of Cycle 2 (each cycle is 28 days)
Percentage of subjects with complete remission (CR) and incomplete hematologic recovery (CRi)
次要结局
- Relapse-Free Survival(24 months)
- Overall Survival(24 months)
- Duration of response(Time interval from morphologic/MRD response to loss of response or death)
- Adverse events(Start of treatment to 2 weeks after end of treatment)
研究者
Xiao-Ning Gao
Chief Physician
Beijing 302 Hospital
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple MyelomaMultiple MyelomaNCT06246162Affiliated Hospital of Nantong University30
已完成
1 期
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaNCT01729845Fred Hutchinson Cancer Center52
进行中（未招募）
1 期
GVM±R in Patients With Relapsed or Refractory Aggressive NHLNon Hodgkin LymphomaNCT05299164Institute of Hematology & Blood Diseases Hospital, China18
Unknown
2 期
A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT05100329CSPC ZhongQi Pharmaceutical Technology Co., Ltd.38
尚未招募
不适用
Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast CancerBreast CancerNCT06156761Cancer Institute and Hospital, Chinese Academy of Medical Sciences24